<unk>  is a combination of a hepatitis C virus NS5A inhibitor, a hepatitis C virus NS3/4A protease inhibitor, and a CYP3A inhibitor that is FDA approved for the treatment of genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis in combination with ribavirin. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include flushing, paresthesia, fatigue, dizziness, skin rash, pruritus, hypercholesterolemia, increased serum triglycerides, diarrhea, nausea, vomiting, abdominal pain, dysgeusia, dyspepsia, increased gamma-glutamyl transferase, musculoskeletal pain, weakness, increased creatine phosphokinase, cough, and oropharyngeal pain.
Ombitasvir, paritaprevir, and ritonavir
Glecaprevir / pibrentasvir
Atazanavir and cobicistat
Sofosbuvir / velpatasvir
Ombitasvir / paritaprevir / ritonavir / dasabuvir
Ledipasvir / sofosbuvir
Sofosbuvir / velpatasvir / voxilaprevir
Elbasvir / grazoprevir